Genmab — November 2018
-
Pollux: 51,2% CR eller bedre. 26,2% MRDneg i 10 i minus 5. Vi skal være opmærksomme på hvilken tærskel, der anvendes i MRD. https://www.ncbi.nlm.nih.gov/pubmed/30237262
-
abstracts via https://ash.confex.com/ash/2018/webprogram/start.html
-
156One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone https://ash.confex.com/ash/2018/webprogram/Paper113183.html
-
-
Genmabs release, a bit easier to find the important ones https://ir.genmab.com/news-releases/news-release-details/genmab-announces-data-be-presented-2018-ash-annual-meeting
-
Thirty-five total abstracts on Genmab owned and partnered programs scheduled for presentation at ASH
•Three abstracts related to Genmab owned programs: DuoBody
-CD3xCD20 & DuoHexaBody
-CD37
•Daratumumab: 5 oral presentations; total of 30 accepted including ISS -
To prove the anti-leukemic activity of daratumumab in AML in vivo https://ash.confex.com/ash/2018/webprogram/Paper113287.html
-
Conclusions: CyBorD-DARA is a highly active, well tolerated induction therapy for NDMM patients undergoing ASCT. https://ash.confex.com/ash/2018/webprogram/Paper112375.html
-
Conclusions:
CyBorD-DARA is a highly active, well tolerated induction therapy for NDMM patients undergoing ASCT. https://ash.confex.com/ash/2018/webprogram/Paper112375.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind